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Abstract
The aim of this study was to culture human fetal bone cells (dedicated cell banks of fetal bone
derived from 14 week gestation femurs) within both hyaluronic acid gel and collagen foam, to
compare the biocompatibility of both matrices as potential delivery systems for bone engineering
and particularly for oral application. Fetal bone cell banks were prepared from one organ donation
and cells were cultured for up to 4 weeks within hyaluronic acid (Mesolis) and collagen foams
(TissueFleece). Cell survival and differentiation were assessed by cell proliferation assays and
histology of frozen sections stained with Giemsa, von Kossa and ALP at 1, 2 and 4 weeks of culture.
Within both materials, fetal bone cells could proliferate in three-dimensional structure at ∼70%
capacity compared to monolayer culture. In addition, these cells were positive for ALP and von
Kossa staining, indicating cellular differentiation and matrix production. Collagen foam provides a
better structure for fetal bone cell delivery if cavity filling is necessary and hydrogels would permit
an injectable technique for difficult to treat areas. In all, there was high biocompatibility, cellular
differentiation and matrix deposition seen in both matrices by fetal bone cells, allowing for easy
cell delivery for bone stimulation in vivo. Copyright  2011 John Wiley & Sons, Ltd.
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1. Introduction
Bone loss is still a clinical problem that attracts the
interest of many investigations in order to determine
an alternative for bone replacement. Specifically for oral
application, bone tissue is necessary to supply areas
to support dental implants or in cases of periodontal
disease, which requires regeneration of functional
bone tissue (Patino et al., 2002; Yildirim et al., 2000;
Mendes et al, 2008). Classical surgery techniques, such
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as autograft, allograft and xenograft for bone tissue
repair, consist of invasive traumatic procedures with
a risk of contamination and immunological response
complications (Younger and Chapman, 1989; Strong
et al., 1996).
To overcome this problem, cell therapy has been
proposed as a less invasive alternative for bone
engineering. Several cell types have been investigated to
be used in cell therapy: embryonic stem cells (ESCs),
umbilical cord cells, fetal cells and adult stem cells
from bone marrow haematopoietic stem cells (HSCs)
and mesenchymal stem cells (MSCs), along with adipose
tissue, platelets, placenta and amniotic fluid cells (Guillot
et al., 2007; Bianco and Robey, 2001; Bullard et al., 2003;
Kaviani et al., 2001; Kaviani et al., 2002; Tobita et al.,
2008; Kruyt et al., 2008). As for any application in tissue
engineering, the cell origin and type are
Copyright  2011 John Wiley & Sons, Ltd.
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essential aspects in bone tissue engineering (Guillot et al.,
2007; Pioletti et al., 2006; Quintin et al., 2007). Stem
cells and cell populations derived at different stages of
development are associated with terminology that can be
quite confusing. Despite the diversity of cell source, each
type of cell requires different methods to manipulate its
differentiation and self-renewal capabilities for specific
therapies, with various advantages and disadvantages
(Table 1, Figure 1).
The relatively simple manipulation of fetal cells in
relation to their collection, culture expansion and storage
has made fetal cells an attractive choice for cell therapy,
as they are tissue-specific, thereby eliminating rigorous
population selection and differentiation by multiple
growth factors. In addition, fetal cells have the advantage
of high proliferation and sustaining a differentiation
state and potential for mineralization activity in vitro
(Montjovent et al., 2004). Unlike ESCs, fetal cells do
not form tumours and seem to lack immunogenicity when
transplanted (Montjovent et al., 2009). Due to the rapid
cellular growth and minimum nutrient requirements of
fetal bone cells, fetal cell banking can be established to
assure high levels of consistency. In contrast to MSCs,
fetal bone cells do not require feeder layers for growth
or specific growth factors for differentiation. One organ
donation is capable of producing a master cell bank
(MCB) that would be available for hundreds of thousands
of patient treatments. The fully defined consistent cell
bank could easily be assessed for safety concerning
any potential virus and pathogens in parallel to the
original organ donation where serology and pathology
are accomplished (Quintin et al., 2007). Among the major
challenges that will assure many patients benefiting from
bone tissue engineering in the future is not only related
to the choice of cell type, their isolation and proliferation
but equally to a biocompatible delivery system for the
chosen cell type.
Previous results from Montjovent et al. (2005) demon-
strate that a composite made of poly-L-lactic acid and
β-tricalcium phosphate particles used as scaffolds to seed
fetal bone cells can offer suitable conditions for osteoblasts
to achieve full differentiation, due to the high osteogenic
potential of these cells. Furthermore, in vivo studies using
dedicated fetal bone cell banks with solid matrix have
shown significant promotion of bone growth using two
different model systems (Montjovent et al., 2005, 2007,
2008).
Several hydrogels, whether synthetic or naturally
derived, have extensive use in medicine, pharmaceutical
and basic sciences (Drury and Mooney, 2003). Hydrogels
provide a hydrated space and a mechanical carrier for cell
transplantation and tissue engineering. The interest for
many studies on hydrogels and collagen-based matrices is
the use of these materials for clinical injectable cell deliv-
ery directly within defect areas for tissue engineering to
minimize surgical procedures (Patino et al., 2002; Drury
and Mooney, 2003; Lutolf and Hubbell, 2005; Alsberg
et al., 2001; Weinand et al., 2006). Collagen has been
incorporated into a variety of medical devices and has
been used for multiple proposes (Mast et al.,1993). For
dental applications, resorbable forms of collagen have
been used to dress oral wounds, for closure of graft and
extraction sites, for delivery of autologous bone residues
and to promote healing (Wang, 1998). In all, biocompat-
ible biomaterials need to be available in order to provide
an extracellular matrix environment for bone cell differ-
entiation and release. In this study, we evaluated the
use of a hydrogel of hyaluronic acid (HA; Mesolis, CE
marked) and a collagen foam (TissueFleece, CE marked
medical device) as human fetal bone cell delivery systems
to verify their biological behaviour and biocompatibility
for bone engineering.
2. Materials and methods
2.1. Bone donations and cell bank synthesis
Cell banks were established in the University Hospital of
Lausanne from a fetal femur bone biopsy at 14 weeks of
gestation (14 wFB), obtained after pregnancy termination
with informed and written consent and approval from
the local Medical School Ethics Committee (Protocol No.
51/01).
Cell banks were prepared from 0.5 cm3 bone biopsy at
passages 2–3. The detailed procedure has been described
previously for fetal skin (de Buys Roessingh et al., 2006;
Quintin et al., 2007) and specific conditions for the
present study are described briefly. A bone biopsy was
dissected into 0.5 mm3 fragments, then approximately
five fragments were distributed into 10 cm culture dishes
previously scored deeply with a sterile scalpel in a
chequer-board pattern under a laminar flow hood. A small
quantity of culture medium containing DMEM with 10%
fetal bovine serum (FBS; Hyclone) was placed around
each fragment to avoid floating of the tissues for the first
24 h; rare floating tissues could be overlaid with a sterile
coverslip for the first 24 h if necessary. After the first 24 h,
an additional 8 ml culture medium were added onto each
10 cm plate and this was changed twice weekly before
passage. Cell cultures were grown at 37 ◦C in a humidified
atmosphere of 95% air/10% CO2.
When cell growth had advanced after approximately
1–2 weeks for fetal bone cells, the dishes of tissue and
cells were trypsinized [0.25% trypsin: 0.1% ethylene
diaminetetra-acetic acid (EDTA)]. At this point, some
fetal bone cells were frozen into individual units in liquid
nitrogen and others were passaged at 2000 cells/cm2 for
producing the MCB, as described previously by Quintin
et al. (2007).
2.2. Fetal bone cell growth within hydrogels
and collagen foam
Cell growth was measured at various time points
following culture of fetal bone cells at passage 4
within hydrogels and collagen matrix. Cells in hydrogels
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Figure 1. Development stage, cell type and source of cells currently used in cellular therapy. Embryonic stem cells are derived from
embryos at an early stage when<100 cells are present, followed by fetal stem cells that are taken from the genital ridge section from
5–8 weeks of gestation (drawing taken from: http://www.wikipedia.org). Tissue-specific fetal cells are taken following 9 weeks of
gestation usually up to 14–16 weeks from normal tissue. Adult stem cells can be isolated from most tissue sources (image taken
from: http://www.national academics.org/stemcells) but are rare, with only 1 in every 104–105 of total cell volume
and collagens were plated in 24-well (hydrogels) and
six-well (collagen) tissue culture dishes at a density
of 10 000 cells/cm2 for hydrogels and 50 000 and
100 000 cells/cm2 (collagen) in triplicate, respectively.
Cell growth medium was over-layered onto the cultures.
Following 1, 3, 6 or 7 and 9 days, samples were
treated with trypsin + EDTA (Gibco) for hydrogels
for 5 min and with trypsin + EDTA + collagenase
(collagenase type II, Clostridium histolyticum, Gibco)
for 30 min at 37 ◦C to separate cells individually from
each sample. Collagenase treatment completely degraded
fibrous collagen to solution form, therefore liberating all
the cells in each sample. Cell counts were elaborated
with the aid of a haemocytometer and an automatic cell
counter and repeated in triplicate.
2.3. Fetal bone biocompatibility with hyaluronic
acid hydrogels and collagen foams
For hyaluronic acid (HA) hydrogels, we used the
hyaluronic acid gel Mesolis (Anteis SA, Geneva,
Switzerland). It was necessary to prepare an agar mould
to avoid cellular attachment to the tube and allow three-
dimensional (3D) growth. The mould was prepared by
pipetting 1 ml melted agarose (20% low-melting agar)
inside a 1.5 ml sterile conical Eppendorf centrifuge tube,
in which a 0.5 ml sterile conical Eppendorf centrifuge
tube was inserted into the liquid agar and allowed to
solidify before extracting the 0.5 ml tube, leaving a conical
inset (Figure 3). HA hydrogel with 10 000 cells/ml were
inserted into the agar mould and 100 µl culture medium
were pipetted onto the surface of each tube; thereafter
the medium was changed twice weekly. The cells were
grown for 1, 2 and 4 weeks in a 37 ◦C incubator at 95%
relative humidity and 10% CO2.
For collagen foam sheet preparations we used
TissueFleece equine collagen sheets of 2 mm thick-
ness dry weight (Baxter, Switzerland). Fetal bone cells
at passages 3 or 4 were placed in 10 ml culture medium
and seeded onto the collagen sheets at a density of
10 000 cells/cm2. The sheets containing the fetal bone
cells were placed into a 37 ◦C incubator at 95% rela-
tive humidity and 10% CO2. An additional 30 ml culture
mediumwas added 1 h later. For collagen foamswith inte-
grated fetal bone cells, the medium was changed twice
weekly with nutrient medium. Fetal bone cell-seeded
collagen foams remained at a 2 mm thickness, like the
original dry collagen sheets.
Biocompatibility was also measured by a contact assay,
in which cells were cultured within a tissue culture plate
where hydrogel or collagen were initially seeded. Cell
growth and migration were analysed visually with respect
to the hydrogel–collagen foam interface. After 1, 2 and
4 weeks, the samples were stained with Giemsa and
photographed (Sony CyberShot DSC-S70, Zeiss macro
lens, zoom ×6, 3.3 megapixels).
As the hydrogels were transparent, cells that had
migrated to the culture plate could easily be photographed
to visually assure biocompatibility with the gel over the
growth period and to assess efficient cell growth with
no change in morphology (Leica DMIL inverse, phase-
contrast with ocular ×10/18 and objective ×10/0.22 C
Plan PH1).
2.4. Fetal bone function and matrix deposition
After 2 and 4 weeks of culture, cells cultivated within
the HA hydrogel inside the agar mould and collagen
were frozen in liquid nitrogen. Sections (20 µm) were
cut and the staining procedures were followed after
fixation of samples with 4% formaldehyde. For detection
of alkaline phosphatase (ALP) activity, we followed
the procedure from Sigma-Aldrich, using p-nitrophenol
tablets as substrate (85L3R-1KT). Staining for von Kossa
(von Kossa-Silver Nitrate; Sigma-S-6506) was applied to
detect clusters of mineralization in the matrix (Bonewald
et al., 2003). Staining with Giemsa was performed to
observe HA hydrogel characteristics as cell support. For
Copyright  2011 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2011;5: 806–814.
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Figure 2. Matrix deposition. Histological sections (20 µm) of fetal bone cells grown for 2 weeks in HA Mesolis hydrogels or Baxter
TissueFleece collagen foams were stained with Giemsa, ALP and von Kossa (×100)
von Kossa staining, cells grown in hydrogels and collagen
foams were washed twice with PBS following fixation,
after which the fixative was removed and the samples
put into 5% silver nitrate solution and then exposed to
UV light for 15 min, followed by a deionized water wash.
Sodium thiosulphate (5% in deionized water) was added
for 3 min, the samples were washed with deionized water
and counterstained with Nuclear fast red (Sigma-Aldrich:
red for nuclei) for 3 min. All samples were mounted with
coverslips and then photographed (Leica, Leitz DMRB,
ocular L Plan×10/0.25 with objectives×10/0.25 N PLAN
or ×20/0.40 N PLAN).
3. Results and discussion
In this study we were interested in evaluating two
commercially available materials for human fetal bone
cell delivery regarding biocompatibility and bone cell
differentiation. In particular, we wanted to test a solid
and a liquid–gel scaffold as different clinical situations
may need one or the other.
After 2 weeks of culture, fetal bone cells were
shown to survive and produce matrix within the
two different cell delivery systems, HA hydrogels and
collagen foams, providing a 3D structure (Figure 2).
Giemsa staining showed the overall ultrastructure of
cells integrated throughout the HA hydrogel and collagen
foam. Hydrogels permitted the cells to proliferate in a
3D semi-liquid form where the cells remained round
in morphology. This was technically possible since the
agar moulds were used to ensure that cellular growth
only occurred in a ‘suspension’ within the hydrogels. If
the hydrogel was placed in plastic tubes or plates, cell
migration towards these surfaces was observed, as these
cells prefer, and grow more rapidly in, a monolayer than
in suspension, as they have adhesion possibilities.
Cell morphology within the collagen foam permitted
a structure similar to that seen when cells are grown
in monolayer tissue culture flasks, showing a fibroblastic
nature. Rapid adhesion withmaterials allows amore rapid
cellular growth and the development of colonies of cells
instead of individual cell growth throughout a matrix.
Within the two cell delivery systems, histology showed
that these cells had markers for differentiated bone (ALP)
and that matrix deposition was evident already (von
Kossa). HA hydrogels or collagen foams alone did not take
up any residual staining for each technique for histological
staining as a control, indicating that it is the cells
themselves producing the matrix deposition over time
(Figure 2). After 4 weeks of culture, cell growth was still
observed and higher matrix deposition was indicated by
von Kossa staining around cells and especially throughout
the collagen foam further away from individual cells. This
time point was mainly to evaluate any potential degrading
by-product following long-term cell–matrix association,
since matrix deposition was seen already at 2 weeks of
3D culture of fetal bone cells, as shown in Figure 2.
3.1. Biocompatibility of fetal bone cells with HA
hydrogel and collagen foam
Biocompatibility of fetal bone cells was assessed by
evaluating whether human fetal bone cells can survive
and proliferate within the HA hydrogel and collagen
(Figure 3). Cells grown within hydrogels and also in
contact with hydrogels within 24-well plates could be
quantified. Visually, the cells were able to proliferate very
well, with the same morphology as those cells that were
not in contact with hydrogel. The cells were counted at
various time points and proliferation was shown to be 70%
of that of cells grown without the presence of hydrogel,
which represents the most rapid condition as they are fully
in monolayer growth (Figure 4A). Cell growth was seen
to increase by three- and five-fold over a 9 day period
Copyright  2011 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2011;5: 806–814.
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Figure 3. Biocompatibility of fetal bone cells with Mesolis
hydrogel and Baxter TissueFleece collagen foams at 4 weeks.
(Top) For the hydrogel, it was necessary to use an agar mould
(photo of tube preparation) to allow cell growth in 3D structure
in suspension and not attaching to plastic surfaces. As the
hydrogels were transparent, cells that had migrated to the
culture plate could easily be photographed to visually assure
biocompatibility with the gel over the growth period and to
assess efficient cell growth with no change in morphology.
(Bottom) Biocompatibility of fetal bone cells with collagen foam
was evaluated by a contact assay in which foams seeded with
cells were cultured within a tissue culture plate, cell growth and
migration were analysed macroscopically and microscopically
and samples were stained with Giemsa and photographed (Sony
CyberShot DSC-S70, Zeiss macro lens, zoom×6, 3.3 megapixels)
(×100). No degradation by-products was observed after 4 weeks
for cells in hydrogel and those grown in monolayer,
respectively. Biocompatibility of fetal bone cells was
evidenced visually over time without toxicity being
observed. Cell morphology remained similar throughout
the experiments, with cells having a fibroblastic nature.
When fetal bone cells were placed in hydrogels inside
plastic tubes or plates that were not tissue-grade quality,
the hydrogel provided a coating for these materials to
allow rapid cellular attachment. Migration of cells was
within 1 h, when all cells were already attached to the
hard surfaces. This could be an important trait for cell
delivery if the hydrogel were used to simplify delivery of
fetal bone cells locally by injection and would assure rapid
migration to attach to host bone structures. The migratory
and adhesion properties of fetal cells have been shown
to be more highly regulated than other cell types used in
tissue and cellular therapy to date (Hirt-Burri et al., 2008;
Ramelet et al., 2009). Biocompatibility was tested using
the agar mould coating to assure no cellular attachment.
Although fetal bone cells prefer adhesion for best growth
capacity, these cells were seen to grow gradually and
remain alive for up to 4 weeks in ‘suspension’ within
the hydrogel, which emphasizes that the hydrogel does
Figure 4. Cell growth. Cell growth is represented in normal cell
culture compared to growth in Mesolis hydrogel (top) or Baxter
collagen foam (bottom), with cell number as a function of days in
culture. Data are representative of three individual experiments
in triplicate with associated standard deviation of the mean
not produce degradative by-products affecting cellular
growth, even after long periods of contact. Overall, neither
hydrogel nor collagen showed degradation or shrinkage
over the 4 week period of cellular growth within and did
not elicit toxicity to the fetal bone cells. Collagen foam
can also provide a support for the cells during the 2 and
4 weeks of cell culture, with no apparent degradation
in vitro. Biocompatibility was also seen to be very high,
as represented by the contact assay, in which cells are
layered around the collagen foam in culture and cells
migrated towards the collagen foam and integrated within
easily (interface of contact between cells and collagen,
Figure 3). Structurally, as it is a solid, collagen foam is
easier to manage for histological procedures than HA
hydrogel, but both can support the cells and provide a
matrix for cell survival, proliferation and differentiation.
The motivation for using commercially available
scaffolds was based on the fact that the specific
chosen materials are already used in different clinical
applications. The translation of the results obtained here
to a clinical application would then be easier than with a
newly developed scaffold that had not been validated. This
aspect is very important when evaluating a combination
product (association of a medical device that already has
approval with clinical-grade cells) for clinical use, as the
association of the two elements should not produce toxic
degradation by-products. Therefore, the biocompatibility
of each of these scaffolds, showing cell proliferation even
after 4 weeks, provides essential information for how live
cells interact with their support for delivery.
As the use of fetal cell therapy has already successfully
been implemented in clinical trials for skin applications
(de Buys Roessingh et al., 2006; Ramelet et al., 2009;
Hohlfeld et al., 2005; Applegate et al., 2009), we now
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have the possibility to propose different delivery systems
using human fetal bone cells for preclinical assessment.
Overall, the results demonstrated good biocompatil-
ity of the two tested scaffolds, namely a hyaluronic
acid hydrogel (Mesolis) and a collagen foam
(TissueFleece). Not only were the viability and prolifera-
tion of fetal cells observed, but also differentiation toward
mature osteoblasts was supported by both scaffolds. These
aspects are obviously a prerequisite in the perspective of
using a material for cell delivery. The results obtained
with the collagen foam are in line with previous stud-
ies. Indeed, human fetal bone cells were shown to fully
differentiate into mature osteoblasts, as demonstrated
by a mineralization assay, when these cells were culti-
vated in foam made of poly-L-lactic acid and β-tricalcium
phosphate particles (Montjovent et al., 2005). In general,
polymer foams seem to be an adequate support for bone
formation. The proliferation and differentiation of fetal
bone cells cultured in HA hydrogel was indeed more
surprising. Osteoblasts or, more generally, fibroblasts are
anchorage-dependant for their development. Hydrogel is
then a scaffold not offering a strong anchorage to cells,
which could be considered to be in a suspension. Not
all hydrogels support the differentiation of osteoblasts;
for example, fibrin gel has been shown to hamper the
proliferation of cells, including MSCs and fetal bone cells.
Surprisingly, the general use of fetal cells in clinics, if
properly done, is more straightforward than with MSCs.
Indeed, one of the major challenges for assuring that
more patients will benefit from cell-based therapies in
the future will be the optimization of the choice of cell
type, as well as their isolation, proliferation and delivery.
The development of MCB from the cell choice provides
a major advantage for the creation of a therapeutic bio-
logical agent. Fetal cells are easily adapted to this type of
development, since only one organ donation is necessary
to develop a MCB from a specific tissue such as fetal bone.
Fetal cells, unlikemany stem cell types, do not need feeder
layers or external growth factors for cell differentiation
processes. Fetal cells are differentiated cells, since they
are derived from specific tissues and organs. Even though
stem cells have an advantage in changing and differentiat-
ing into multiple cell lineages, it is difficult to assure their
final cell type differentiation when placed in vivo. Once
MCB can be produced, working cell banks can be set
up to establish individual batches of treatments for high
numbers of patients (for skin and bone, this can be up to
hundreds of thousands of patients from one cell-banking
process and from one organ donation). Further, these cell
banks can be completely tested for safety regarding steril-
ity, pathogens, adventitious agents and tumorigenicity.
Despite its important potential, the ethical and related
emotional aspects of developing a fetal cell therapy should
not be underestimated, and in particular there is consid-
erable misinformation about this subject. Although there
is high medical support for developing cell-based thera-
pies to reach as many patients as possible, there exists
a governing political controversy. In the 1930s, medical
doctors and scientists used tissue from voluntary preg-
nancy interruptions, not only to aid in the understanding
of cell biology but also as an important entity in the devel-
opment of vaccines, by using defined tissue-derived cell
lines. The Nobel Prize for Medicine in 1954 was awarded
to American immunologists who developed the polio vac-
cine based on cultures of human fetal cells. Since this time,
many other necessary vaccines (rubella, chicken pox, hep-
atitis A, etc.) have been developed with the use of fetal
cell lines, including two primary human diploid cell lines
which were originally prepared in the 1960s – the WI-38
(Wistar Institute 38) in 1964 and the MRC-5 (Medical
Research Council 5) in 1966. In Switzerland and most
countries, fetal tissue is considered as an organ dona-
tion by law (Heinonen et al., 2005; Trommelmans et al.,
2007, 2008; Pfeffer and Kent, 2006; Kent and Pfeffer,
2006). This process is highly regulated, including federal
approval for tissue biopsy, stocking and transplantation
and ethics committee approval of the procedure, with
elaborate protocols for informed consent of the donor
(Commission of the European Communities Proposal for
a Regulation of the European Parliament and of the
Council on Advanced Therapy Medicinal Production and
Amending Directive 2001/83/EC and Regulation (EC)
No. 726/2004; ‘Setting standards of quality and safety
for the donation, procurement, testing, processing, stor-
age, and distribution of human tissues and cells’. Off J
European Union 2001; L 102/48).
Not only is the cell choice pertinent, but equally impor-
tant will be the delivery system of the cell type and its
interaction with these scaffolds to assure biocompatibility
and that no toxic degradation by-products are formed.
Collagen foams, similar to those used for skin regen-
eration, are used routinely by dental surgeons. Before
closing wounds for dental implants, many dental sur-
geons place the bone pulp that is removed from the
drill-hole procedure onto a collagen sponge before closing
the wound. In the same manner, collagen foams provide a
first measure of cell presentation. For better stimulation of
osseo-intergration, fetal bone cells could be delivered dur-
ing the closing procedure to reduce the non-load period
following the dental implant. Further stimulation of tis-
sue repair could be delivered by an injectable form of cell
delivery, which could be in a hydrogel format. We have
seen that fetal bone cells adapt well to hyaluronic acid and
have a viscosity that is readily injected through very small
needle bores without affecting cell survival. Hyaluronic
acid (HA) is a molecule abundant in the human body. Its
molecular architecture allows the crosslinking to proteo-
glycan and collagen which makes HA useful as a carrier
for cells. Additionally, HA facilitates cell migration to the
surrounding tissue that could allow rapid cell delivery for
bone repair in vivo (Drury and Mooney, 2003; Weinand
et al., 2006). Collagen-based materials have been used as
a membrane barrier in oral application. Collagen is a very
usefulmaterial because of its biocompatibility, absorption,
chemotactic qualities and also the capability of enhancing
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migration and filling space (Patino et al., 2002). There-
fore, the vast functional diversity of these two cell carriers
could potentially be used together for overall treatment.
4. Conclusions
In this study, human fetal bone cell delivery was inves-
tigated using two different biomaterials. The biocom-
patibility and cell differentiation by observing cellular
matrix deposition was evaluated in 3D cell culture. When
using equine collagen foam and hyaluronic acid hydro-
gel, not only were the viability and proliferation of fetal
cells observed but also differentiation toward mature
osteoblasts was supported by both scaffolds. Collagen
foam, due to its resistant properties, could be used as
a cell carrier for initial treatment in areas that need a
bone support and a hyaluronic acid gel as a sustained
therapy for rapid and localized cell delivery to damaged
host bone when additional bone stimulation would be
needed. Importantly, we observed that both collagen and
HA sustained their structure over the 4 weeks of culture
and provided a support for cell survival, proliferation and
differentiation. Overall, cellular therapies could provide
an interesting alternative to single growth factor delivery
(Nikolidakis et al., 2009) for bone regeneration, given in
non-physiological dosages to the patient.
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